Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 1, 2014, Pages 53-61

  Grimwade, David ^a   Jovanovic, Jelena V ^a   Hills, Robert K ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

acute promyelocytic leukaemia; minimal residual disease; personalized medicine; PML RARA; polymerase chain reaction; real time quantitative

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; GEMTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ANTINEOPLASTIC AGENT; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR MARKER;

ALLOTRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; BLOOD; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; EPIDEMIOLOGY; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; PATHOLOGY; PROCEDURES; REMISSION; SALVAGE THERAPY;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; HISTORICALLY CONTROLLED STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; OXIDES; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; SALVAGE THERAPY; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84902134132     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.04.002     Document Type: Review

References (30)

1. D. Grimwade, A.R. Mistry, and E. Solomon et al. Acute promyelocytic leukemia: a paradigm for differentiation therapy Cancer Treat Res 145 2010 219 235
2. D. Grimwade, A. Biondi, and M.J. Mozziconacci et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies Blood 96 2000 1297 1308
3. M.A. Sanz, D. Grimwade, and M.S. Tallman et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 113 2009 1875 1891
4. H. de Thé, and Z. Chen Acute promyelocytic leukaemia: novel insights into the mechanisms of cure Nat Rev Cancer 10 2010 775 783
5. F. Guidez, S. Parks, and H. Wong et al. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia Proc Natl Acad Sci U S A 104 2007 18694 18699
6. A.K. Burnett, D. Grimwade, and E. Solomon et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial Blood 93 1999 4131 4143
7. D. Grimwade, J.V. Jovanovic, and R.K. Hills et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy J Clin Oncol 27 2009 3650 3658
8. S. Lehmann, A. Ravn, and L. Carlsson et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry Leukemia 25 2011 1128 1134
9. J.H. Park, B. Qiao, and K.S. Panageas et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid Blood 118 2011 1248 1254
10. D. Grimwade The significance of minimal residual disease in patients with t(15;17) Best Pract Res Clin Haematol 15 2002 137 158
11. F. Lo Coco, D. Diverio, and G. Avvisati et al. Therapy of molecular relapse in acute promyelocytic leukemia Blood 94 1999 2225 2229
12. J. Esteve, L. Escoda, and G. Martín et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention Leukemia 21 2007 446 452
13. C. Santamaría, M.C. Chillón, and C. Fernández et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia Haematologica 92 2007 315 322
14. R. Flora, and D. Grimwade Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML Methods Mol Med 91 2004 151 173
15. J. Gabert, E. Beillard, and V.H. van der Velden et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program Leukemia 17 2003 2318 2357
16. A.K. Burnett, R.K. Hills, and D. Grimwade et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial Leukemia 27 2013 843 851
17. M. Yanada, M. Tsuzuki, and H. Fujita et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia Blood 121 2013 3095 3102
18. R. Thirugnanam, B. George, and E. Chendamarai et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen Biol Blood Marrow Transpl 15 2009 1479 1484
19. G. Meloni, D. Diverio, and M. Vignetti et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene Blood 90 1997 1321 1325
20. E. Lengfelder, F. Lo-Coco, and L. Ades et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: updated results of the European registry of relapsed APL (PROMYSE) American Society of Hematology annual meeting 2013 Abstract #1406
21. F. Lo-Coco, A. Romano, and A. Mengarelli et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease Leukemia 17 2003 1930 1933
22. M. Breccia, D. Diverio, and N.I. Noguera et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy Haematologica 89 2004 29 33
23. D. Grimwade, R. Jamal, and N. Goulden et al. Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid Br J Haematol 103 1998 559 562
24. E. Estey, G. Garcia-Manero, and A. Ferrajoli et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood 107 2006 3469 3473
25. F. Ravandi, E. Estey, and D. Jones et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin J Clin Oncol 27 2009 504 510
26. F. Lo-Coco, G. Avvisati, and M. Vignetti et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia N Engl J Med 369 2013 111 121
27. G. Avvisati, F. Lo-Coco, and F.P. Paoloni et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance Blood 117 2011 4716 4725
28. S.J. Chen, G.B. Zhou, and X.W. Zhang et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Blood 117 2011 6425 6437
29. B.D. Cheson, J.M. Bennett, and K.J. Kopecky et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 2003 4642 4649
30. J.V. Jovanovic, K. Rennie, and D. Culligan et al. Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia Front Oncol 1 2011 35